title: Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.
abstract: BACKGROUND
  Adrenocortical carcinoma is a rare tumor with a poor prognosis. This work was aimed at analyzing the clinical outlook and treatment results of 52 patients with this disease.
  
  
  METHODS
  This study included patients with adrenocortical carcinoma referred to the Department of Endocrinology at the Center of Postgraduate Medical Education (Warsaw, Poland) during the last 30 years. In 11 patients, the adrenal tumor was found incidentally by ultrasonographic scan. Hormonal examinations made it possible to define the endocrine activity of the tumors, whereas imaging techniques helped to determine their staging. Forty-eight patients underwent surgery, and 36 of them received mitotane. This drug was administered to 26 patients for a range of 10 months to 10 years; 13 patients received mitotane immediately after the operation, and 13 others after a delay. The patients with severe hypercorticism were pretreated before surgery with aminoglutethimide and mitotane.
  
  
  RESULTS
  The study comprised 10 men and 42 women; hormonally active tumors were diagnosed in 39 of them. Cushing's syndrome was the most frequent entity. At diagnosis, 17 cases were classified as localized disease, 15 as regional disease, and 20 as distant disease. Pretreatment with the inhibitors of steroidogenesis improved the survival perspectives in the early postoperative period. As of this writing, there were 12 survivors in the group of 26 patients treated by surgery and long term mitotane therapy and only 2 survivors of 7 patients treated with surgery only.
  
  
  CONCLUSIONS
  Surgery with immediate adjuvant long term mitotane administration was the most effective form of therapy for patients with adrenocortical carcinoma.
authors.affiliation: Department of Endocrinology, Center of Postgraduate Medical Education, Warsaw, Poland.
authors.forename: A A
authors.initials: AA
authors.lastname: Kasperlik-Załuska
authors.forename: B M
authors.initials: BM
authors.lastname: Migdalska
authors.forename: S
authors.initials: S
authors.lastname: Zgliczyński
authors.forename: A M
authors.initials: AM
authors.lastname: Makowska
mesh_terms: D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D018268:Adrenocortical Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000616:Aminoglutethimide / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003480:Cushing Syndrome / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000097:blood; D013007:Growth Hormone-Releasing Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use; D009367:Neoplasm Staging; D015996:Survival Rate; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
chemical_list: D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000616:Aminoglutethimide; D013739:Testosterone; D008939:Mitotane; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D006854:Hydrocortisone